Skip to content

Study · Animal study (in vivo) · mouse · 2024

11 results

Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection.

Lin C, Luo L, Xun Z, Zhu C, Huang Y, Ye Y, Zhang J, Chen T, Wu S, Zhan F, Yang B, Liu C, Ran N, Ou Q

Gut5 Jan 2024Cited by 21 (Europe PMC)

PMID37788894 (opens in a new tab)DOI10.1136/gutjnl-2023-330389 (opens in a new tab)PepBankPUB-37788894
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In HBV-infected mice, MOTS‑c inhibited HBV replication; the abstract gives a 50-70% inhibition rate without separating cell results from mouse results.

    In plain wordsIn HBV-infected mice, MOTS‑c reduced virus copying; the 50-70% rate is not split between cells and mice.

    Peptide
    MOTS-c
    Outcome
    DecreaseHBV replication inhibition in vivo
    Study

    mousen: not reported in source

    HBV-infected mice
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Measurements

    HBV replication inhibition rate
    50 to 70%
    in vitro or in vivo

    Source sentences

    Summary
    Inhibition of HBV replication (with a 50-70% inhibition rate) was observed alongside improved liver function without notable toxicity in vitro or in vivo.
    1 context sentence
    Summary · context
    The therapeutic effect of MOTS-c was observed in multiple HBV-infected mice and cells through various techniques, including transcriptomic sequencing, flow cytometry, immunofluorescence and electron microscopy.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In HBV-infected mice, MOTS‑c treatment was accompanied by improved liver function.

    In plain wordsIn HBV-infected mice, liver function improved alongside MOTS‑c treatment.

    Peptide
    MOTS-c
    Outcome
    IncreaseLiver function
    Study

    mousen: not reported in source

    HBV-infected mice
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Inhibition of HBV replication (with a 50-70% inhibition rate) was observed alongside improved liver function without notable toxicity in vitro or in vivo.
    1 context sentence
    Summary · context
    The therapeutic effect of MOTS-c was observed in multiple HBV-infected mice and cells through various techniques, including transcriptomic sequencing, flow cytometry, immunofluorescence and electron microscopy.
  3. 03AnimalAnimal study (in vivo)Safety outcome

    In HBV-infected mice, no notable toxicity of MOTS‑c was observed.

    In plain wordsIn HBV-infected mice, MOTS‑c showed no notable toxicity.

    Peptide
    MOTS-c
    Outcome
    No significant changeToxicity in vivo
    Study

    mousen: not reported in source

    HBV-infected mice
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Inhibition of HBV replication (with a 50-70% inhibition rate) was observed alongside improved liver function without notable toxicity in vitro or in vivo.
    1 context sentence
    Summary · context
    The therapeutic effect of MOTS-c was observed in multiple HBV-infected mice and cells through various techniques, including transcriptomic sequencing, flow cytometry, immunofluorescence and electron microscopy.
  4. 04LabIn vitro (cells)Efficacy outcome

    In HBV-infected cells, MOTS‑c inhibited HBV replication; the abstract gives a 50-70% inhibition rate without separating cell results from mouse results.

    In plain wordsIn lab-grown HBV-infected cells, MOTS‑c reduced virus copying; the 50-70% rate is not split between cells and mice.

    Peptide
    MOTS-c
    Outcome
    DecreaseHBV replication inhibition in vitro
    Study

    n: not reported in source

    HBV-infected cells
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Measurements

    HBV replication inhibition rate
    50 to 70%
    in vitro or in vivo

    Source sentences

    Summary
    Inhibition of HBV replication (with a 50-70% inhibition rate) was observed alongside improved liver function without notable toxicity in vitro or in vivo.
    1 context sentence
    Summary · context
    The therapeutic effect of MOTS-c was observed in multiple HBV-infected mice and cells through various techniques, including transcriptomic sequencing, flow cytometry, immunofluorescence and electron microscopy.
  5. 05LabIn vitro (cells)Safety outcome

    In HBV-infected cells, no notable toxicity of MOTS‑c was observed.

    In plain wordsIn lab-grown HBV-infected cells, MOTS‑c showed no notable toxicity.

    Peptide
    MOTS-c
    Outcome
    No significant changeToxicity in vitro
    Study

    n: not reported in source

    HBV-infected cells
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Inhibition of HBV replication (with a 50-70% inhibition rate) was observed alongside improved liver function without notable toxicity in vitro or in vivo.
    1 context sentence
    Summary · context
    The therapeutic effect of MOTS-c was observed in multiple HBV-infected mice and cells through various techniques, including transcriptomic sequencing, flow cytometry, immunofluorescence and electron microscopy.
  6. 06LabIn vitro (cells)Mechanism

    In HBV models, MOTS‑c promoted mitochondrial biogenesis.

    In plain wordsIn lab models of HBV infection, MOTS‑c promoted the making of new mitochondria.

    Peptide
    MOTS-c
    Outcome
    IncreaseMitochondrial biogenesis
    Study

    n: not reported in source

    HBV-infected cells
    Outcome group
    Mitochondrial function · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c was found to promote mitochondrial biogenesis and enhance the MAVS (mitochondrial antiviral signalling protein) signalling pathway.
    1 context sentence
    Summary · context
    The therapeutic effect of MOTS-c was observed in multiple HBV-infected mice and cells through various techniques, including transcriptomic sequencing, flow cytometry, immunofluorescence and electron microscopy.
  7. 07LabIn vitro (cells)Mechanism

    In HBV models, MOTS‑c enhanced the MAVS (mitochondrial antiviral signalling protein) signalling pathway.

    In plain wordsIn lab models of HBV infection, MOTS‑c strengthened the MAVS antiviral signal pathway.

    Peptide
    MOTS-c
    Outcome
    IncreaseMAVS signalling pathway
    Study

    n: not reported in source

    HBV-infected cells
    Outcome group
    Receptor activity and mechanism · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MOTS-c was found to promote mitochondrial biogenesis and enhance the MAVS (mitochondrial antiviral signalling protein) signalling pathway.
    1 context sentence
    Summary · context
    The therapeutic effect of MOTS-c was observed in multiple HBV-infected mice and cells through various techniques, including transcriptomic sequencing, flow cytometry, immunofluorescence and electron microscopy.
  8. 08LabIn vitro (cells)Mechanism

    In HBV models, the antiviral impact of MOTS‑c depended on its ability to regulate MYH9-actin-mediated mitochondrial homeostasis.

    In plain wordsIn lab models of HBV infection, the antiviral effect of MOTS‑c depended on its control of the MYH9-actin system.

    Peptide
    MOTS-c
    Outcome
    Not applicableDependence on MYH9-actin-mediated mitochondrial homeostasis
    Study

    n: not reported in source

    HBV-infected cells
    Outcome group
    Receptor activity and mechanism · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The impact is dependent on MOTS-c's ability to regulate MYH9-actin-mediated mitochondrial homeostasis.
    1 context sentence
    Summary · context
    The therapeutic effect of MOTS-c was observed in multiple HBV-infected mice and cells through various techniques, including transcriptomic sequencing, flow cytometry, immunofluorescence and electron microscopy.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 09HumanEndogenous levelObservational studyOther

    In people with HBV infection, MOTS‑c levels correlated negatively with HBV DNA expression (R=-0.71).

    In plain wordsIn people with HBV infection, the body's own MOTS‑c levels were lower when virus DNA levels were higher.

    Peptide
    MOTS-c
    Outcome
    Not applicableCorrelation of MOTS-c with HBV DNA
    Study

    n: not reported in source

    Outcome group
    Antiviral activity · Infection

    Measurements

    Correlation coefficient (R)
    −0.71 NA
    MOTS-c with HBV DNA

    Source sentences

    Summary
    MOTS-c negatively correlates with HBV DNA expression (R=-0.71), and its AUC (the area under the curve) for distinguishing CHB from healthy controls is 0.9530, and IA (immune reactive) from IC (inactive HBV carrier) is 0.8689.
    2 context sentences
    Summary · context
    In total, 85 healthy subjects and 404 patients with HBV infection, including 20 clinical treatment cohorts, were recruited for this study.
    Summary · context
    MOTS-c levels were measured by ELISA and its diagnostic value was evaluated by receiving operating characteristic curve analysis.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

  2. 10HumanEndogenous levelObservational studyOther

    In people with HBV infection, MOTS‑c levels distinguished chronic hepatitis B from healthy controls with an AUC of 0.9530.

    In plain wordsThe body's own MOTS‑c level separated people with chronic hepatitis B from healthy people with high accuracy.

    Peptide
    MOTS-c
    Outcome
    Not applicableDiagnostic AUC of MOTS-c, chronic hepatitis B versus healthy controls
    Study

    n: not reported in source

    Comparator
    Healthy controls
    Outcome group
    Antiviral activity · Infection

    Measurements

    AUC
    0.953 NA
    CHB vs healthy controls

    Source sentences

    Summary
    its AUC (the area under the curve) for distinguishing CHB from healthy controls is 0.9530
    2 context sentences
    Summary · context
    In total, 85 healthy subjects and 404 patients with HBV infection, including 20 clinical treatment cohorts, were recruited for this study.
    Summary · context
    MOTS-c levels were measured by ELISA and its diagnostic value was evaluated by receiving operating characteristic curve analysis.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

  3. 11HumanEndogenous levelObservational studyOther

    In people with HBV infection, MOTS‑c levels distinguished immune reactive (IA) from inactive carrier (IC) patients with an AUC of 0.8689.

    In plain wordsThe body's own MOTS‑c level separated immune-reactive from inactive-carrier HBV patients with good accuracy.

    Peptide
    MOTS-c
    Outcome
    Not applicableDiagnostic AUC of MOTS-c, immune reactive versus inactive carrier
    Study

    n: not reported in source

    Comparator
    Inactive HBV carriers
    Outcome group
    Antiviral activity · Infection

    Measurements

    AUC
    0.8689 NA
    IA vs IC

    Source sentences

    Summary
    and IA (immune reactive) from IC (inactive HBV carrier) is 0.8689
    2 context sentences
    Summary · context
    In total, 85 healthy subjects and 404 patients with HBV infection, including 20 clinical treatment cohorts, were recruited for this study.
    Summary · context
    MOTS-c levels were measured by ELISA and its diagnostic value was evaluated by receiving operating characteristic curve analysis.

    This result measures the body's own MOTS-c. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.